Company: CNTB
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001835268-25-000014
Chunk: 40

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-03-31
Form: 10-K
Item: Item 15
Chunk 40
---
 Director Compensation Program20-F001-402124.54/16/202410.6†Employment Agreement, effective as of January 1, 2021, between Connect Biopharm LLC and Zheng Wei, Ph.D.F-1333-25363110.112/26/202110.7†Executive Employment Agreement, effective as of January 1, 2021, between Connect Biopharma HongKong Limited and Wubin Pan, Ph.D.F-1333-25363110.122/26/202110.8†Employment Offer Letter, dated October 13, 2021, between Connect Biopharm LLC and Steven Chan20-F001-402124.103/31/202210.9House Lease Contract, effective as of May 1, 2023 between Suzhou Connect Biopharma Co., Ltd. and Taicang Science and Technology Venture Park Co., Ltd. (English Translation)6-K001-4021299.16/23/202310.10Lease, effective as of December 22, 2021, by and between Connect Biopharm LLC and Paseo Del Mar LLC20-F001-402124.133/31/202210.11*Exclusive License and Collaboration Agreement, dated November 21, 2023, by and among Connect Biopharma HongKong Limited, Suzhou Connect Biopharma Co., Ltd. and Simcere Pharmaceutical Co., Ltd. (English Translation)6-K001-4021299.111/21/202310.12†2024 Employment Inducement Incentive Award Plan and form of share option grant notice and share option agreement thereunder6-K001-4021210.16/12/202410.13†Employment Agreement, effective as of June 12, 2024, between Connect Biopharm LLC and its affiliates and Barry Quart6-K001-4021210.26/12/202410.14†Employment Agreement, effective as of June 12, 2024, between Connect Biopharm LLC and its affiliates and David Szekeres6-K001-4021210.36/12/202410.15†Employment Offer Letter, dated August 7, 2024, between Connect Biopharm LLC and Lisa PerazaFiled

156

TABLE OF CONTENTS

10.16†Addendum to Employment Offer Letter for Severance Benefits, dated August 7, 2024, between Connect